Literature DB >> 27746228

Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin.

Andreas Beyer1, Holger Grohganz2, Korbinian Löbmann3, Thomas Rades4, Claudia S Leopold5.   

Abstract

Co-amorphization represents a promising approach to increase the physical stability and dissolution rate of amorphous active pharmaceutical ingredients (APIs) as an alternative to polymer glass solutions. For amorphous and co-amorphous systems, it is reported that the preparation method and the blend ratio play major roles with regard to the resulting physical stability. Therefore, in the present study, co-amorphous naproxen-indomethacin (NAP/IND) was prepared by melt-quenching at three different cooling rates and at ten different NAP/IND blend ratios. The samples were analyzed using XRPD and FTIR, both directly after preparation and during storage to investigate their physical stabilities. All cooling methods led to fully amorphous samples, but with significantly different physical stabilities. Samples prepared by fast cooling had a higher degree of crystallinity after 300d of storage than samples prepared by intermediate cooling and slow cooling. Intermediate cooling was subsequently used to prepare co-amorphous NAP/IND at different blend ratios. In a previous study, it was postulated that the equimolar (0.5:0.5) co-amorphous blend of NAP/IND is most stable. However, in the present study the physically most stable blend was found for a NAP/IND ratio of 0.6:0.4, which also represents the eutectic composition of the crystalline NAP/γ-IND system. This indicates that the eutectic point may be of major importance for the stability of binary co-amorphous systems. Slight deviations from the optimal naproxen molar fraction led to significant recrystallization during storage. Either naproxen or γ-indomethacin recrystallized until a naproxen molar fraction of about 0.6 in the residual co-amorphous phase was reached again. In conclusion, the physical stability of co-amorphous NAP/IND may be significantly improved, if suitable preparation conditions and the optimal phase composition are chosen. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Binary; Co-amorphous; Composition; Cooling; Equimolar; Eutectic; Physical stability

Mesh:

Substances:

Year:  2016        PMID: 27746228     DOI: 10.1016/j.ejpb.2016.10.002

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  5 in total

1.  Melt Extrusion of High-Dose Co-Amorphous Drug-Drug Combinations : Theme: Formulation and Manufacturing of Solid Dosage Forms Guest Editors: Tony Zhou and Tonglei Li.

Authors:  Lærke Arnfast; Md Kamruzzaman; Korbinian Löbmann; Johanna Aho; Stefania Baldursdottir; Thomas Rades; Jukka Rantanen
Journal:  Pharm Res       Date:  2017-09-19       Impact factor: 4.200

Review 2.  Co-amorphous Drug Delivery Systems: a Review of Physical Stability, In Vitro and In Vivo Performance.

Authors:  Qin Shi; Yanan Wang; Sakib M Moinuddin; Xiaodong Feng; Fakhrul Ahsan
Journal:  AAPS PharmSciTech       Date:  2022-09-19       Impact factor: 4.026

Review 3.  Co-Amorphous Solid Dispersions for Solubility and Absorption Improvement of Drugs: Composition, Preparation, Characterization and Formulations for Oral Delivery.

Authors:  Anna Karagianni; Kyriakos Kachrimanis; Ioannis Nikolakakis
Journal:  Pharmaceutics       Date:  2018-07-19       Impact factor: 6.321

4.  Determination of Stable Co-Amorphous Drug-Drug Ratios from the Eutectic Behavior of Crystalline Physical Mixtures.

Authors:  Eric Ofosu Kissi; Keyoomars Khorami; Thomas Rades
Journal:  Pharmaceutics       Date:  2019-11-24       Impact factor: 6.321

Review 5.  Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies.

Authors:  Jingwen Liu; Holger Grohganz; Korbinian Löbmann; Thomas Rades; Nele-Johanna Hempel
Journal:  Pharmaceutics       Date:  2021-03-15       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.